Discover our service packages
Modular support, from high-level strategic review
to structured development risk deliverables.
Translational Safety Blueprint
A strategic review of the asset’s safety profile, current investigator's brochure (IB), foreseeable risks, mechanistic hypotheses, competition context and mitigation perspectives.
Asset audit and mechanistic analysis
Literature and competition review
Foreseeable risk mapping
Expert report with perspectives
Development Risk Management Plan (DRMP)
A comprehensive DRMP focused on known, potential and foreseeable risks, with surveillance and mitigation proposals.
Risk consideration and characterization
Additional preclinical investigation needs
Suggested AESI design and surveillance
Structured DRMP deliverable
Due Diligence
Independent evaluation of safety robustness and benefit/risk implications to support informed investment and business decisions.
Clinical and preclinical safety data assessment
Business impact of safety uncertainties
Red flag / yellow card / green light perspective
Strategic opinion with mitigation options
Advisory Board
& Funds Support
Independent strategic support for portfolio, governance, clinical trial safety and reputational safety concerns.
Challenge safety assumptions
Support investment and acquisition diligence
Assess hidden liabilities and weak governance
Position benefit/risk against competition
ClinDeRisk partners with stakeholders who need high-value, independent and scientifically grounded safety insight.
Who we work with
Biotech, pharma, CRO and veterinary stakeholders
Companies developing chemical, biological, immunological, vaccine, or veterinary assets, or engaged in specialized development programs
Investors and funds
Venture capital firms, family offices, business angels and institutional investors assessing asset safety and benefit/risk profiles.
Public skateholders
Regulatory agencies, funding bodies requiring independent strategic input.